TY - JOUR
T1 - Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds
AU - Kim, Jinku
AU - Sharma, Aditi
AU - Runge, Brett
AU - Waters, Heather
AU - Doll, Bruce
AU - Mcbride, Sean
AU - Alvarez, Pedro
AU - Dadsetan, Mahrokh
AU - Yaszemski, Michael J.
AU - Hollinger, Jeffrey O.
PY - 2012/5
Y1 - 2012/5
N2 - Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.
AB - Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.
KW - Bone tissue engineering
KW - Poly(ε-caprolactone fumarate)
KW - Rabbit calvarial critical-sized defect
KW - RhBMP-2
KW - Three-dimensional scaffold
UR - http://www.scopus.com/inward/record.url?scp=84860012874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860012874&partnerID=8YFLogxK
U2 - 10.1002/term.442
DO - 10.1002/term.442
M3 - Article
C2 - 21744511
AN - SCOPUS:84860012874
SN - 1932-6254
VL - 6
SP - 404
EP - 413
JO - Journal of Tissue Engineering and Regenerative Medicine
JF - Journal of Tissue Engineering and Regenerative Medicine
IS - 5
ER -